With improved life expectancy to a median age of 48 years in sickle-cell disease and to a median of 68 years in sicklecell-hemoglobin C disease, 1 patients with these diagnoses are increasingly developing both hematologic malignancy and other neoplasms. [2] [3] [4] Many of these malignancies may benefit from autologous hematopoietic stem cell transplantation. However, filgrastim administered to mobilize hematopoietic stem cells may precipitate severe and sometimes fatal sickle crisis in patients with sickle-cell anemia or complex sickle-cell hemoglobinopathies. [5] [6] A previous single report describes successful autologous marrow transplantation in a patient with sickle-cell disease and diffuse large-cell lymphoma. 2 Filgrastim was used to support initial chemotherapy and was also administered post transplantation without clinical evidence of sickle-cell crisis. We now report a successful filgrastim mobilized hematopoietic stem cell transplantation for diffuse largecell lymphoma in a patient with sickle-cell hemoglobin C disease.
A 22-year-old male with a history of hemoglobin SC disease (HbSC) (1-2 mild-to-moderate sickle-cell pain crisis per year and recent penile prosthesis for recurrent priapism) was diagnosed with stage IV large-cell B-cell non-Hodkin's lymphoma with a high International Prognostic Index score (LDH-691, performance status-2, stage IV). He had persistent disease after seven cycles of rituximab, cyclophosphamide, adriamycin, vincristine and prednisone (R-CHOP) chemotherapy. While receiving prophylactic doses of filgrastim during the first two cycles of R-CHOP chemotherapy, he experienced severe sickle pain crises requiring hospitalization. Filgrastim was therefore not used in subsequent cycles. Two cycles of salvage rituximab, etoposide, cisplatin, cytarabine and methylprednisone (R-ESHAP) chemotherapy established that his disease was chemo-sensitive and an autologous hemopoietic stem cell transplant was planned. Given the history of sickle crisis with previous use of filgrastim, he was monitored after chemotherapy alone but mobilized insufficient CD34 þ cells. We therefore performed an exchange transfusion using 10 units of peripheral red blood cells before stem cell mobilization with filgrastim, lowering HbS from 20 to 6%. Following rebound from ifosphamide and etoposide chemotherapy (third salvage cycle), filgrastim was initiated in a split dose schedule (total dose, 10 mg/kg divided in to two equal doses administered twice a day) in order to minimize the risk of hyperleucocytosis. The total white blood cell count following 5 days of filgrastim was 18.7 Â 10 9 /l and CD34 þ cells 29/ml. A total of 6.8 Â 10 6 /kg CD34 þ cells were collected through 2 apheresis procedures. He then received high-dose chemotherapy with rituximab 375 mg/m 2 Â 1 day, carmustine 300 mg/m 2 Â 1 day, cytarabine 400 mg/m 2 Â 4 days, etoposide 400 mg/m 2 Â 4 days and melphalan 140 mg/m 2 Â 1 day (R-BEAM) and had rapid and sustained myeloid and platelet engraftment on days 9 and 10, respectively, without post transplant filgrastim. Engraftment was complicated by a moderately severe pain crisis similar to his previous filgrastim related crises that improved over 7 days. Of note, he developed hypophosphatemia at engraftment that required intensive replacement therapy. Post transplant restaging revealed a residual 2.5 cm lesion in the pelvis with no other evidence of disease; he is currently undergoing external beam radiation to the residual site.
An attempt was made to procure AMD-3100 (Mobozil), [7] [8] [9] an irreversible antagonist of CXCR4 that inhibits attraction between the homing molecule stromal cellderived factor-1 and the CXCR4 receptor on the stem cells in an attempt to collect stem cells without hyperleucocytosis, but regulatory issues prevented use of the drug in a timely manner. As granulocyte colony-stimulating factor has been safe in the sickle trait donors, 10 we opted to collect filgrastim mobilized stem cells following an exchange transfusion.
The mechanism by which leucocytosis precipitates sickle crisis remains an enigma. It may be that phosphate depletion secondary to rapid phosphate utilization in leukocyte genesis leads to reduction of red cell 2-3 diphosphoglycerate (DPG) resulting in tissue hypoxia and polymerization of stressed red cell. Reduced 2-3 DPG levels has been demonstrated in patients with hypophosphatemia. 11 This patient had hypophosphatemia related to engraftment 12 that may have contributed to the crisis at that time. We conclude that a modified filgrastim schedule, along with exchange transfusion successfully mobilized stem cells in a patient with HbSC disease and, given that such patients may be at risk of sickle crisis during engraftment, vigilant phosphate monitoring is prudent. 
